Phase 2 Parkinson's Disease Trial, Recruiting NCT03836950 Sponsor: VA Office of Research and Development Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 2 Parkinson's Disease Trial, Recruiting

NCT03836950
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be a Veteran who receives care at Hines VA Hospital or Jesse Brown VA Medical Center
  • You must have been diagnosed with Parkinson's disease or a related movement disorder by a neurologist
  • You must have been found to have mild cognitive impairment (some memory or thinking difficulties, but not dementia)
  • You must be on a stable medication routine, meaning no recent changes to your medications or doses, and no changes are expected during the study
  • You must be able to speak and read English
  • You must be 50 years of age or older

Who may not be able to join:

  • People who have been diagnosed with dementia
  • People who are not able to make their own decisions about taking part in the study
  • People who have had deep brain stimulation surgery
  • People with severe depression
  • People who have a strong resting head tremor (shaking of the head while still)
  • People whose involuntary movements (such as writhing or jerking) would interfere with brain imaging
  • People who have congestive heart failure
  • People who have an implanted heart pacemaker or defibrillator
  • People who have a cochlear implant, nerve stimulator, or metal clips inside the skull
  • People who have an implanted medical pump of any kind
  • People with increased pressure inside the skull (confirm with trial site)
  • People who have a history of claustrophobia (fear of enclosed spaces)
  • People who have metal in their eyes or face, or shrapnel or bullet fragments in the brain
  • People who may be at higher risk of having a seizure, including those with a personal or family history of seizures or epilepsy, a history of stroke or head injury, or other neurological conditions that may affect seizure risk
  • People taking certain medications such as tricyclic antidepressants, antipsychotic medications, or any other drug known to increase the risk of seizures
  • People with other health conditions that may significantly affect the body's chemical balance or increase seizure risk
  • People for whom a specific brain stimulation dose cannot be accurately measured or determined (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sandra L. Kletzel, PhD BA, Edward Hines Jr. VA Hospital, Hines, IL

Phone: (708) 202-5735

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 April 2020
Est. completion
31 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

change in NIH sponsored Executive Abilities: Measures and Instruments for neurobehavioral evaluation and re-search (NIH-EXAMINER) executive composite score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov